An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer.

Nat Commun · 2020 · PMC7755894 · PMID 33353953

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The optimal dose of NARA1leukin was determined to correspond to 0.5 μg hIL-2 equivalent, as higher doses did not further increase CD8 + T and NK cell expansion but showed a trend toward toxicity (Supplementary Fig. 1 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.